Calcitonin Gene Related Peptide Monoclonal Antibodies in the Treatment of Migraine: Is There a Difference in Efficacy Between Inhibitors of the Ligand Compared to Inhibitors of the Receptor?
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- There were no significant differences in treatment response between patients treated with a CGRP monoclonal antibody to the receptor or with a monoclonal antibody to the CGRP ligand.
- Thus, inhibiting the ligand or inhibiting the canonical receptor are equally effective in reducing headache frequency and improving quality of life.
- Limitations include small sample size of the ligand receptor inhibitor cohort and lack of generalizability of data to patients outside of a large tertiary Headache center.
Presenting Author
Zubair Ahmed, MD
Assistant Professor of Neurology Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland Clinic
Cleveland, Ohio
Dr. Zubair Ahmed completed his neurology residency at the Cleveland Clinic where he served as chief resident. He completed his headache fellowship at the University of Utah. During his fellowship he was awarded the Frontiers in Headache Research Scholarship by the American Headache Society. His research interests lie in patient reported outcomes research. Dr. Ahmed is currently an assistance professor of neurology at the Cleveland Clinic.
Author disclosures
Zubair Ahmed, MD: Allergan (Speaking and Teaching) (Consulting Fees (e.g., advisory boards)) Eli Lilly (Consulting) (Consulting Fees (e.g., advisory boards)) Teva (Independent Contractor (Including Contracted Research)) (Research Grant)
